{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:41:13Z","timestamp":1790030473750,"version":"4.0.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ Cardiovasc Genet"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n            <jats:title>Background\u2014<\/jats:title>\n            <jats:p>Clinical trials testing pharmacogenomic-guided warfarin dosing for patients with atrial fibrillation have demonstrated conflicting results. Non\u2013vitamin K antagonist oral anticoagulants are expensive and contraindicated for several conditions. A strategy optimizing anticoagulant selection remains an unmet clinical need.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Results\u2014<\/jats:title>\n            <jats:p>Characteristics from 14\u2009206 patients with atrial fibrillation were integrated into a validated warfarin clinical trial simulation framework using iterative Bayesian network modeling and a pharmacokinetic\u2013pharmacodynamic model. Individual dose\u2013response for patients was simulated for 5 warfarin protocols\u2014a fixed-dose protocol, a clinically guided protocol, and 3 increasingly complex pharmacogenomic-guided protocols. For each protocol, a complexity score was calculated using the variables predicting warfarin dose and the number of predefined international normalized ratio (INR) thresholds for each adjusted dose. Study outcomes included optimal time in therapeutic range \u226565% and clinical events. A combination of age and genotype identified different optimal protocols for various subpopulations. A fixed-dose protocol provided well-controlled INR only in normal responders \u226565, whereas for normal responders &lt;65 years old, a clinically guided protocol was necessary to achieve well-controlled INR. Sensitive responders \u226565 and &lt;65 and highly sensitive responders \u226565 years old required pharmacogenomic-guided protocols to achieve well-controlled INR. However, highly sensitive responders &lt;65 years old did not achieve well-controlled INR and had higher associated clinical events rates than other subpopulations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions\u2014<\/jats:title>\n            <jats:p>Under the assumptions of this simulation, patients with atrial fibrillation can be triaged to an optimal warfarin therapy protocol by age and genotype. Clinicians should consider alternative anticoagulation therapy for patients with suboptimal outcomes under any warfarin protocol.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circgenetics.117.001804","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T10:05:41Z","timestamp":1513159541000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Personalized Anticoagulation"],"prefix":"10.1161","volume":"10","author":[{"given":"Kourosh","family":"Ravvaz","sequence":"first","affiliation":[{"name":"From the Aurora Research Institute, Aurora Health Care, Milwaukee, WI (K.R., J.A.W.); Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA (C.T.R., P.J.T.); School of Nursing and Institute for Health Informatics, University of Minnesota, Minneapolis (C.-L.C.); and University of Wisconsin, Milwaukee (P.J.T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Weissert","sequence":"additional","affiliation":[{"name":"From the Aurora Research Institute, Aurora Health Care, Milwaukee, WI (K.R., J.A.W.); Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA (C.T.R., P.J.T.); School of Nursing and Institute for Health Informatics, University of Minnesota, Minneapolis (C.-L.C.); and University of Wisconsin, Milwaukee (P.J.T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Ruff","sequence":"additional","affiliation":[{"name":"From the Aurora Research Institute, Aurora Health Care, Milwaukee, WI (K.R., J.A.W.); Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA (C.T.R., P.J.T.); School of Nursing and Institute for Health Informatics, University of Minnesota, Minneapolis (C.-L.C.); and University of Wisconsin, Milwaukee (P.J.T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Lin","family":"Chi","sequence":"additional","affiliation":[{"name":"From the Aurora Research Institute, Aurora Health Care, Milwaukee, WI (K.R., J.A.W.); Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA (C.T.R., P.J.T.); School of Nursing and Institute for Health Informatics, University of Minnesota, Minneapolis (C.-L.C.); and University of Wisconsin, Milwaukee (P.J.T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Tonellato","sequence":"additional","affiliation":[{"name":"From the Aurora Research Institute, Aurora Health Care, Milwaukee, WI (K.R., J.A.W.); Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA (C.T.R., P.J.T.); School of Nursing and Institute for Health Informatics, University of Minnesota, Minneapolis (C.-L.C.); and University of Wisconsin, Milwaukee (P.J.T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2012.09.021"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.922061"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/1076029615614395"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.07.013"},{"key":"e_1_3_4_6_2","first-page":"23","article-title":"Well-managed warfarin is superior to NOACs.","volume":"61","author":"Trusler M","year":"2015","unstructured":"Trusler M. Well-managed warfarin is superior to NOACs. Can Fam Physician. 2015;61:23\u201324.","journal-title":"Can Fam Physician"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-06-0443"},{"key":"e_1_3_4_8_2","first-page":"31","article-title":"The community pharmacy-based anticoagulation management service achieves a consistently high standard of anticoagulant care.","volume":"128","author":"Harper P","year":"2015","unstructured":"Harper P, McMichael I, Griffiths D, Harper J, Hill C. The community pharmacy-based anticoagulation management service achieves a consistently high standard of anticoagulant care. N Z Med J. 2015;128:31\u201341.","journal-title":"N Z Med J"},{"key":"e_1_3_4_9_2","first-page":"232","article-title":"Quality of anticoagulation control among patients with atrial fibrillation.","volume":"17","author":"Melamed OC","year":"2011","unstructured":"Melamed OC, Horowitz G, Elhayany A, Vinker S. Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care. 2011;17:232\u2013237.","journal-title":"Am J Manag Care"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14841-6"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000258004.64840.0b"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.464"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1103053"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809329"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.13"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0341"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-04-0290"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1108"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500417"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2006.078139"},{"key":"e_1_3_4_21_2","unstructured":"US Food and Drug Administration. Warfarin (Coumadin) product labeling. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/009218s107lbl.pdf. Accessed March 23 2017."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.737312"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.070920"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311386"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310669"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.123034"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100084"},{"key":"e_1_3_4_28_2","first-page":"505","article-title":"Improving patient adherence to warfarin therapy.","volume":"17","author":"Cruess DG","year":"2010","unstructured":"Cruess DG, O\u2019Leary K, Platt AB, Kimmel SE. Improving patient adherence to warfarin therapy. JCOM. 2010;17:505\u2013509.","journal-title":"JCOM"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/107602960100700108"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apnr.2016.12.002"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12709"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1651587"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2008.04.005"},{"key":"e_1_3_4_34_2","volume-title":"R: A language and Environment for Statistical Computing [Computer Program]","author":"R Core Team","year":"2016","unstructured":"R Core Team. R: A language and Environment for Statistical Computing [Computer Program]. Vienna, Austria: R Foundation for Statistical Computing; 2016."},{"key":"e_1_3_4_35_2","volume-title":"An {R} Companion to Applied Regression [Computer Program]","author":"Fox J","year":"2011","unstructured":"Fox J, Weisberg S. An {R} Companion to Applied Regression [Computer Program]. Thousand Oaks, CA: Sage; 2011."},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.10.49"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61994-2"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311388"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-0054"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.190"}],"container-title":["Circulation: Cardiovascular Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCGENETICS.117.001804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T01:24:02Z","timestamp":1715563442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCGENETICS.117.001804"}},"subtitle":["Optimizing Warfarin Management Using Genetics and Simulated Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1161\/CIRCGENETICS.117.001804"],"URL":"https:\/\/doi.org\/10.1161\/circgenetics.117.001804","relation":{},"ISSN":["1942-325X","1942-3268"],"issn-type":[{"value":"1942-325X","type":"print"},{"value":"1942-3268","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"e001804"}}